Cirrhosis

Regional metabolic liver function measured in patients with cirrhosis by 2-[18F]fluoro-2-deoxy-D-galactose PET/CT

Michael Sørensen[1,2,*,†], Kasper S. Mikkelsen[1,†], Kim Frisch[1], Gerda E. Villadsen[2], Susanne Keiding[1,2]

[1]Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark; [2]Department of Medicine V (Hepatology/Gastroenterology), Aarhus University Hospital, Aarhus, Denmark

Background & Aims: There is a clinical need for methods that can quantify regional hepatic function non-invasively in patients with cirrhosis. Here we validate the use of 2-[18F]fluoro-2-deoxy-D-galactose (FDGal) PET/CT for measuring regional metabolic function to this purpose, and apply the method to test the hypothesis of increased intrahepatic metabolic heterogeneity in cirrhosis.

Methods: Nine cirrhotic patients underwent dynamic liver FDGal PET/CT with blood samples from a radial artery and a liver vein. Hepatic blood flow was measured by indocyanine green infusion/Fick's principle. From blood measurements, hepatic systemic clearance (K_{syst}, L blood/min) and hepatic intrinsic clearance (V_{max}/K_m, L blood/min) of FDGal were calculated. From PET data, hepatic systemic clearance of FDGal in liver parenchyma (K_{met}, mL blood/mL liver tissue/min) was calculated. Intrahepatic metabolic heterogeneity was evaluated in terms of coefficient-of-variation (CoV, %) using parametric images of K_{met}.

Results: Mean approximation of K_{syst} to V_{max}/K_m was 86% which validates the use of FDGal as PET tracer of hepatic metabolic function. Mean K_{met} was 0.157 mL blood/mL liver tissue/min, which was lower than 0.274 mL blood/mL liver tissue/min, previously found in healthy subjects ($p < 0.001$), in accordance with decreased metabolic function in cirrhotic livers. Mean CoV for K_{met} in liver tissue was 24.4% in patients and 14.4% in healthy subjects ($p < 0.0001$). The degree of intrahepatic metabolic heterogeneity correlated positively with HVPG ($p < 0.05$).

Conclusions: A 20-min dynamic FDGal PET/CT with arterial sampling provides an accurate measure of regional hepatic metabolic function in patients with cirrhosis. This is likely to have clinical implications for the assessment of patients with liver disease as well as treatment planning and monitoring.

Introduction

It has become increasingly evident that liver cirrhosis is not necessarily a static end point of parenchymal liver disease, but can indeed be dynamic and potentially reversible. This has, together with the increasing use of local treatments, for e.g., liver tumours in patients with cirrhosis, led to an increased clinical demand for non-invasive methods that can quantify stiffness and metabolic functions of the liver [1]. It is also of clinical interest to be able to predict remnant liver function following e.g., partial liver resection, by estimating regional-to-global liver function, especially in patients with parenchymal liver disease [2]. In Japan, hepatic scintigraphy with measurements of the asialoglycoprotein receptor density with 99mTc-galactosylneoalbumin (99mTc-GSA) is used for assessment of liver function, but the method is not approved in Europe or the USA [2]. Another method is hepatobiliary scintigraphy (and more recently single photon emission computer tomography, SPECT) with 99mTc-mebrofenin, a substrate that is taken up from blood by hepatocytes and excreted unmetabolized into bile [2]. Hepatic uptake and excretion of 99mTc-mebrofenin are, however, impaired by hypoalbuminemia and high levels of plasma bilirubin, as well as impaired bile flow [2]. Furthermore, scintigraphy suffers from poor spatial and temporal resolutions compared to e.g. positron emission tomography (PET).

We recently developed a molecular imaging method for *in vivo* quantification of hepatic galactokinase capacity using dynamic PET/CT and the galactose analogue 2-[18F]fluoro-2-deoxy-D-galactose (FDGal) [3–5]; the galactokinase enzyme metabolizes galactose and analogues hereof and is almost exclusively found in the liver. The capacity of the liver to remove intravenously injected galactose is measured with the galactose elimination capacity (GEC) test [6,7]. The GEC test yields a measure of global metabolic liver function and provides prognostic information for patients with acute [8,9] and chronic [10,11] liver disease, as well as for patients undergoing hepatic resection [12]. However, the GEC test does not provide any information on potential intrahepatic metabolic heterogeneity. FDGal PET/CT offers a unique possibility to study regional variations in metabolic function in terms of hepatic galactokinase activity [5]. In our study in healthy subjects, the FDGal PET/CT measurements were validated against direct measurements of hepatic removal kinetics of galactose and FDGal by blood measurements from

ELSEVIER

Research Article

an artery and a liver vein [5]. The aim of the present study was to validate the use of FDGal PET/CT for non-invasive 3D quantification of regional hepatic galactokinase capacity in patients with liver cirrhosis, and to apply the method to test the hypothesis of an increased heterogeneity of galactokinase capacity in liver cirrhosis.

Patients and methods

Study design

A 60-min dynamic liver FDGal PET/CT with blood sampling from a radial artery and a liver vein was performed with simultaneous determination of hepatic blood flow by indocyanine green infusion/Fick's principle. Blood concentration measurements of FDGal in arterial and liver venous blood and hepatic blood flow measurements were used to validate FDGal as a PET/CT tracer for galactokinase capacity. The FDGal PET/CT scan and arterial blood samples were used to measure galactokinase capacity in liver parenchyma as well as metabolic heterogeneity.

Patients

Ten patients with liver cirrhosis were included in the study; one patient was excluded due to technical problems with the PET/CT scanner causing the experiment to be cancelled. The patients were included from the outpatient clinic at the Department of Medicine V (Hepatology/Gastroenterology), Aarhus University Hospital. Patients referred to the department for hepatic venous pressure gradient (HVPG) measurement, by liver vein catheterization, were offered to participate in the study. Patients were instructed not to take any food or drugs for 8 hours before the study, but were allowed to drink water. None of the patients received medical treatment for portal hypertension at the time of the study. Patient characteristics are given in Table 1. No patients with hepatocellular carcinoma (HCC) were included as we know that HCC nodules may have increased accumulation of FDGal [13].

Ethics

The study was approved by The Central Denmark Region Committees on Biomedical Research Ethics and conducted in accordance with the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients. The mean radiation dose received by each subject was 4 mSv. No complications to the procedures were observed.

Galactose elimination capacity test

As part of the standard clinical work-up, a GEC test was performed in all patients. The GEC provides an estimate of the maximum removal rate of galactose (mmol/min) for the whole liver, i.e., global galactokinase capacity [6,7]. The result is normalized to provide an index of the metabolic function of the liver as a fraction of the expected value for a healthy individual of the same sex, age, and body weight (normalized GEC; Table 1).

Catheterizations

Catheters were placed in a cubital vein in both arms and in a radial artery. For blood sampling and HVPG measurement, a 6F catheter (Cook Catheter, Bjaeverskov, Denmark) was placed in a liver vein in the right liver lobe, via an introducer catheter in the right femoral vein. The HVPG was calculated as the difference between pressures measured in the wedged and free position in the liver vein.

Hepatic blood flow

An intravenous infusion of indocyanine green (Hyson, Wescott and Dunning, Baltimore, MD, USA) was started 90 min before the PET study. During the PET study, four pairs of blood samples (5 mL each) were collected from the radial artery and the liver vein for spectrophotometric determination of plasma concentrations of indocyanine green [15,16]. Good approximation to steady state concentrations was obtained in each subject and individual mean concentrations from the artery and liver vein were used to calculate an individual mean hepatic blood flow (F, L blood/min) according to Fick's principle with adjustment for individual hematocrit values [17].

FDGal PET/CT and blood measurements

The subjects were placed on their back in a 64-slice Siemens Biograph TruePoint PET/CT camera (Siemens AG, Erlangen, Germany). A topogram of the abdomen was performed for optimal positioning of the liver within the 21.6 cm transaxial field-of-view of the PET camera followed by low-dose CT scan (50 effective mAs with CAREDose4D, 120 kV, pitch 0.8, slice thickness 5 mm) for definition of anatomical structures and attenuation correction of PET data. A bolus of 100 MBq FDGal in 10 mL saline was administered intravenously during the initial 15 sec of a 60-min dynamic PET recording. FDGal was produced in our own radiochemistry laboratory (radiochemical purity ⩾97%) [18]. PET data were reconstructed using iterative processing and a time-frame structure of 18×5, 15×10, 4×30, 4×60, and 10×300 s (total 60 min) and corrected for radioactive decay back to start of the recording.

Table 1. Patient characteristics.

Subject	Sex/age (yr)	Body weight (kg)	Etiology	Albumin (g/L plasma)	Bilirubin (µmol/L plasma)	ALT (U/L plasma)	ALP (U/L plasma)	Child-Pugh class	MELD score	Normalized GEC	HVPG (mmHg)
1	Male/61	70	Alcohol	43	14	43	n.a.	A	6	0.62	12.0
2	Male/66	86	Alcohol	37	11	28	80	B	8	0.60	18.5
3	Female/60	82	Cryptogenic	40	12	39	96	A	8	0.48	19.9
4	Male/57	79	Alcohol + HCV	35	18	121	155	B	8	0.45	30.5
5	Female/71	83	Cryptogenic	41	17	n.a.	n.a.	A	8	0.65	23.5
6	Male/50	93	Alcohol	36	11	23	98	B	8	0.51	22.0
7	Male/62	90	Alcohol	35	10	14	91	B	10	0.55	22.7
8	Male/65	62	Alcohol	33	20	21	104	B	13	0.49	24.0
9	Male/43	70	Alcohol	40	4	13	91	A	8	0.81	18.0

Albumin (reference interval 36–45 g/L plasma); bilirubin (reference interval 5–25 µmol/L plasma); ALT, alanine aminotransferase (reference interval 10–70 units/L plasma); ALP, alkaline phosphatase (reference interval 35–105 units/L plasma); n.a., not available; Child-Pugh class, patients were scored according to the Child-Pugh classification [14]; normalized GEC, galactose elimination capacity (GEC) normalized to the expected value from a healthy subject of same body weight, age, and sex; HVPG, hepatic venous pressure gradient; HCV, hepatitis C virus.

Table 2. Hepatic removal kinetics of FDGal in patients with liver disease.

Subject	K_{met} (ml blood/ml liver tissue/min)	Metabolic heterogeneity in terms of CoV of K_{met}
1	0.166 ± 0.005	20.0%
2	0.197 ± 0.002	19.7%
3	0.196 ± 0.002	25.8%
4	0.150 ± 0.001	29.9%
5	0.159 ± 0.002	23.5%
6	0.121 ± 0.002	29.8%
7	0.149 ± 0.002	26.1%
8	0.145 ± 0.002	22.0%
9	0.199 ± 0.002	22.9%
Mean ± SE	**0.157 ± 0.001***	**24.4 ± 3.8***
Corresponding values from healthy subjects (from [5])		
Mean (range)	0.274 (0.213-0.342)	14.4 (9.2-17.9)

K_{met}, hepatic systemic clearance of FDGal calculated from volume-of-interest-based analysis of PET data.
CoV, coefficient-of-variation calculated as the standard deviation of K_{met} in liver tissue divided by the mean K_{met}.
Individual values for patients are given as estimate ± the standard error of the estimate; mean ± SE, weighted mean ± standard error of the weighted mean.
Bottom row shows data from 8 healthy subjects as mean (range) [5].
*p <0.001 when compared to the healthy subjects (Student's t-test).

During the PET study, arterial and liver vein blood samples (0.5 mL) were collected manually at 18×5, 6×10, 3×20, 3×60, 1×120, 1×240, 1×360, and 4×600 sec for determination of FDGal blood concentrations. Radioactivity concentrations (kBq/mL blood in A, arterial and V, liver venous blood) were measured in a well counter (Packard Instruments, Meriden, CT, USA) and corrected for radioactive decay back to start of the PET recording.

Validation of FDGal as a PET tracer for galactokinase capacity

The hepatic extraction fraction of FDGal was calculated as $E = (A−V)/A$ using mean values of A and V from blood samples collected in the interval 6–20 min after FDGal injection (quasi-steady state metabolism) and corrected for a mean splanchnic transit time of 1 min [19]. The intrinsic clearance of hepatic FDGal metabolism (V_{max}/K_m; L blood/min) was calculated as [20]

$$V_{max}/K_m = −F \ln(1 − E) \qquad (1)$$

The hepatic systemic clearance of FDGal (K_{syst}, L blood/min) was calculated as [20]

$$K_{syst} = F\left(1 - e^{-\frac{V_{max}}{FK_m}}\right) \qquad (2)$$

For the FDGal PET/CT method to provide a measurement of galactokinase capacity, K_{syst} must be predominantly enzyme-determined [5]. For $V_{max}/K_m \ll F$, K_{syst} approximates V_{max}/K_m and is predominantly enzyme-determined; for $V_{max}/K_m \gg F$, K_{syst} approximates F and is predominantly flow-determined [20]. The approximations were assessed quantitatively as the ratios $K_{syst}/(V_{max}/K_m)$ and K_{syst}/F, respectively.

Image analysis

A volume-of-interest was drawn in the right liver lobe using the fused PET/CT images, and the time-course of radioactivity concentration in liver tissue (Bq/mL liver tissue versus time in minutes) in this volume-of-interest was extracted. The hepatic systemic clearance of FDGal in the liver (K_{met}, mL blood/mL liver tissue/min) was determined according to the Gjedde-Patlak representation of data [21,22], assuming irreversible metabolism of FDGal [3,5]. Because this is the first study in cirrhotic patients, we performed the PET recording for 60 min. A detailed analysis of data showed that data from 6 to 20 min after FDGal administration were optimal for the Gjedde-Patlak analysis, similar to what we found in healthy subjects [5]. The volume-of-interest-based analysis was used to determine the optimal time period and to verify that the hepatic FDGal metabolism is irreversible before proceeding to the image-based analysis of functional heterogeneity from parametric images of K_{met}.

Parametric images of K_{met} were created by applying the Gjedde-Patlak analysis to each voxel in the dynamic PET recordings using data from 6–20 min after FDGal administration and the time-course of FDGal in arterial blood as input function. Parametric images thus yield K_{met} values for each voxel during quasi-steady state metabolism. The parametric images were used to assess metabolic heterogeneity within the liver in terms of the coefficient-of-variation (CoV) for K_{met}.

For comparison, parametric images were created from dynamic FDGal PET/CT data from healthy subjects collected using the same PET/CT protocol as in the present study [5]; in Table 2, data from 8 healthy subjects are included but due to technical problems with one set of PET/CT files, parametric images could only be created for 7 healthy subjects.

Statistical analysis

Calculation of K_{met} of FDGal from the PET data, as defined by the Gjedde-Patlak relation (linear regression), employed maximum likelihood estimation. Individual data are given as mean ± standard error of the estimate. Population means were calculated as the weighted mean of the individual estimates using the inverse estimated squared standard errors as weight. Comparisons between mean values from patients and healthy subjects were made using Student's t-test; p <0.05 was considered to indicate a statistically significant difference. Correlation between CoV and HVPG was tested by the Pearson product–moment correlation coefficient, r, with p <0.05 considered to indicate a statistically significant correlation.

Results

Hepatic blood flow

Mean hepatic blood flow was 0.95 L blood/min (range, 0.75–1.50 L blood/min), which was not significantly different from the mean value of 0.94 L blood/min (range, 0.70–1.76 L blood/min) found in healthy subjects [5] (p >0.30).

Validation of FDGal as a tracer for measurement of galactokinase capacity

Mean $V_{max}/(FK_m)$ was 0.28 (range, 0.23–0.41), which means that the hepatic systemic clearance of FDGal is enzyme-dependent, validating the use of hepatic systemic clearance of FDGal as a measure of enzymatic capacity [20]. In accordance with this, the mean approximation of K_{syst} to V_{max}/K_m was 86% (range, 82–90%). This makes FDGal an ideal tracer for *in vivo* measurements of hepatic galactokinase capacity by dynamic PET/CT in patients with cirrhosis of the liver and we could thus proceed with FDGal as a tracer for measurements of regional galactokinase capacity.

FDGal PET/CT of regional hepatic galactokinase capacity and metabolic heterogeneity

The volume-of-interest-based analysis of the dynamic PET/CT data yielded linear Gjedde-Patlak plots for all patients, in agreement with irreversible metabolic trapping of FDGal; this forms the basis for generating parametric images (see below). Individual values of K_{met} are given in Table 2; the mean value of 0.157 mL blood/mL liver tissue/min (range, 0.121–0.199) was significantly lower than the mean K_{met} of 0.274 L blood/L liver tissue/min (range, 0.213–0.342), previously found in healthy subjects [5] (p <0.001). The PET measure of the metabolic capacity per volume liver tissue was thus significantly lower in the patients than in healthy subjects.

The volume-of-interest-based analysis of PET data validated the use of the kinetic model applied to data and formed the basis

Cirrhosis

Research Article

Fig. 1. Examples of parametric images of the hepatic systemic clearance of FDGal (K_{met}, mL blood/mL tissue/min) generated from dynamic FDGal PET/CT recordings. Top row is from a cirrhotic patient (panels A and B) and bottom row is from a healthy subject (panels C and D). Left images are transaxial, right images coronal. The patient is a 57-year-old male with cirrhosis (alcohol and hepatitis C virus), a global liver function of 45% of expected value as measured by a galactose elimination capacity (GEC) test, and portal hypertension (HVPG, 30.5 mmHg).

for generating parametric images of K_{met}. Fig. 1 shows examples of parametric images of K_{met} in a patient with cirrhosis (Panels A and B) and a healthy subject (Panels C and D). In patients, mean CoV for K_{met} in liver tissue was 24.4% (range, 19.7–29.9), which was significantly higher than the mean value of 14.4% (range, 9.2–17.9) ($p < 0.0001$) in healthy subjects (Table 2).

The relationships between metabolic heterogeneity in terms of CoV for K_{met} and global metabolic liver function (normalized GEC), regional metabolic liver function (K_{met}) and HVPG are plotted in Fig. 2A–C. As seen, there was a trend towards negative correlations between increased metabolic heterogeneity in patients and decreased global and local metabolic liver function, but the correlations did not reach statistically significance ($p = 0.16$ for CoV against normalized GEC; $p = 0.13$ for CoV against K_{met}). A positive correlation between the metabolic heterogeneity in the liver parenchyma and HVPG was found in the patients ($p < 0.05$). No significant correlations were found between MELD score and normalized GEC, K_{met} for FDGal, metabolic heterogeneity or HVPG ($p > 0.3$ for all).

Discussion

There is a clinical desire for non-invasive methods that can evaluate regional metabolic function and heterogeneity hereof in a single investigation. In the present study, we show that the metabolic function in cirrhotic livers can be measured in terms of galactokinase activity by a relatively short (20 min) dynamic FDGal PET/CT scan. This enables measurements of metabolic liver function for both the whole liver (global function) or any region of interest (regional function), in a single investigation. Compared to biopsies, which are invasive with potentially serious complications, and which represent only a very small part of the liver, FDGal PET/CT provides functional information on the whole liver, it is a safe procedure, and it can be repeated several times, e.g., to monitor metabolic liver function and the degree of heterogeneity following treatment.

The hypothesis that patients with cirrhosis have an increased intrahepatic metabolic heterogeneity when compared to healthy subjects was verified. Based on the fact that liver histology exhibits considerable heterogeneity when affected by parenchymal disease regardless of aetiology [23–26], this finding may not be


Fig. 2. Intrahepatic metabolic heterogeneity plotted against global and regional metabolic function and HVPG. The intrahepatic metabolic heterogeneity is expressed in terms of the coefficient-of-variation (CoV) for K_{met} (mL blood/mL liver tissue/min) of hepatic FDGal metabolism. Individual values from cirrhotic patients and healthy subjects are plotted against (A) global metabolic liver function, (B) regional metabolic liver function, and (C) HVPG. There was a positive correlation between CoV and HVPG in these patients; the correlation is shown by the straight line with 95% confidence intervals (r = 0.69; $p < 0.05$).

surprising but the present study is, to the best of our knowledge, the first study to use a validated method to demonstrate this.

Hepatic metabolism of galactose, and thus of FDGal, has several advantages for *in vivo* measurements of hepatic metabolic function; the galactokinase enzyme is almost exclusively found in the liver, the metabolism follows Michaelis-Menten kinetics and it is not regulated by hormones such as insulin or glucagon [5,27,28]. Due to a high substrate specificity of galactokinase, FDGal has a weaker interaction with the enzyme than galactose, which, for the present purpose, is an advantage because of the hepatic removal kinetics of FDGal thus is predominantly

enzyme-determined. This means that only changes in enzymatic capacity, i.e., metabolic function, and not changes in e.g., hepatic blood flow, will be reflected by this measure [29]. Furthermore, the approximation of K_{syst} to V_{max}/K_m was found to be similar to that in healthy subjects [5]. This is important because changes in the PET measure over time can be then ascribed directly to changes in the metabolic capacity. K_{syst} was used to validate the PET measure K_{met} because both measures are systemic clearances, the only difference being that K_{syst} is for the whole liver (global) and K_{met} provides a regional measure in terms of per ml liver tissue.

By demonstrating the presence of significantly increased intrahepatic metabolic heterogeneity in cirrhotic livers, we underline the importance of regional evaluation of cirrhotic livers in order to predict remnant liver function following e.g., partial liver resection. By applying the present method in conjunction with diagnostic contrast-enhanced CT, the mean K_{met} for FDGal in any region of the liver can be quantified in relation to the K_{met} for the whole liver, i.e., a regional-to-global estimation of metabolic liver function. This estimate can be used to assess remnant metabolic liver function following surgery and it would be interesting to make a direct comparison between metabolic function in terms of K_{met} for FDGal and histological appearance in the removed part of the liver. Another important issue that now can be addressed is the comparison between the volume of the part being removed and the relative liver function. This is particularly interesting in patients with heterogeneous livers because a removal of, e.g., 25% of the liver, may result in a significantly different change in liver function [2]. FDGal PET/CT also enables studies of the regional effects of stereotactic radiation therapy of liver tumours on metabolic function in surrounding liver tissue function [30]. As discussed above, this measure will be unbiased by any changes in blood perfusion in treated areas because it is predominantly enzyme-determined.

While the importance of hemodynamic changes in terms of increased vascular resistance and portal hypertension for the development of clinical complications in liver disease is well known, little is known about the interplay between regional metabolic liver function and HVPG. Recent studies have shown that in established cirrhosis, septal thickness and the amount of fibrosis, namely changes that each contributes to increased histological heterogeneity, are predictors of the presence of HVPG $\geqslant 10$ mmHg [31,32], suggesting a correlation between the structural changes and clinically significant portal hypertension. An interesting finding in the present study is the positive correlation between HVPG and the intrahepatic heterogeneity in metabolic function because it indicates a potential role of functional imaging with FDGal PET/CT in the overall clinical evaluation of patients with cirrhosis. The method presented here may thus become of prognostic significance with regards to the development of clinical complications in patients with liver cirrhosis because it enables, for the first time, a non-invasive evaluation of the metabolic function of the cirrhotic liver, which may even be more accurate than more indirect markers, such as albumin or bilirubin. All patients in the present study had relatively low MELD scores, which correlated with neither normalized GEC nor HVPG. The apparent correlation between HPVG and metabolic heterogeneity suggests that functional evaluation of the liver by FDGal PET/CT may improve the evaluation of patients, especially those with low MELD scores, but this needs to be tested in a larger prospective study.

In Denmark, alcohol is the leading aetiological factor for cirrhosis and in the present study, only one patient with hepatitis C virus was included. We are confident, however, that the method will also prove useful for monitoring metabolic liver function in patients treated for HCV or patients with other liver diseases. Also, due to the logistics of the project, only patients with Child-Pugh scores A and B were included in the present study, but the short FDGal PET/CT method without liver vein blood sampling is applicable also to patients in Child-Pugh class C. For ethical reasons, we included patients who were referred for HVPG measurement because calculation of K_{syst} required collection of blood from a liver vein. We would like to emphasize that the liver vein catheter is not necessary for determination of K_{met} for FDGal from PET/CT data; for future studies, a short (20 min) dynamic PET/CT study with arterial blood sampling is thus sufficient for quantification of hepatic metabolic function in terms of metabolic clearance of FDGal. The inclusion criterion caused the HVPG measurements to be relatively high with the lowest HVPG value being 12 mmHg, meaning that all patients had clinically significant portal hypertension, but we are confident that the FDGal PET/CT method is also valuable for patients with lower pressure gradients. Because FDGal is produced by a method similar to the one used for routine production of the widely used glucose tracer 2-[18F]fluoro-2-deoxy-D-glucose (FDG) [18], the tracer can be produced in most PET facilities and the radioactive half-life of FDGal (110 min) means that it can be transported to nearby centres, abolishing the need for an onsite cyclotron. Accordingly, the FDGal PET/CT method is likely to become commonly available for evaluation of regional liver function.

In conclusion, we have validated the use of FDGal PET/CT for measuring global and regional metabolic function in the cirrhotic liver in terms of galactokinase capacity by a short (20 min) FDGal PET/CT recording. We also demonstrate a substantial intrahepatic metabolic heterogeneity in cirrhotic livers, which correlated positively with HVPG. This could become important in the assessment of the clinical severity of liver disease and thus have direct clinical implications for non-invasive investigation of patients with liver cirrhosis, but this needs to be validated in a larger study.

Research Article

References

[1] Pinzani M, Vizzutti F, Arena U, et al. Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5:95–106.

[2] de Graaf W, Bennink RJ, Veteläinen R, van Gulik TM. Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med 2010;51:742–752.

[3] Sørensen M, Munk OL, Mortensen FV, Olsen AK, Bender D, Bass L, et al. Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography. Am J Physiol Gastrointest Liver Physiol 2008;295:G27–G36.

[4] Sørensen M. Determination of hepatic galactose elimination capacity using 2-[18F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model. Scand J Gastroenterol 2011;46:98–103.

[5] Sørensen M, Mikkelsen KS, Frisch K, Bass L, Bibby BM, Keiding S. Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT. J Nucl Med 2011;52:1566–1572.

[6] Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest 1966;18:118–125.

[7] Tygstrup N. Effect of sites of blood sampling in determination of the galactose elimination capacity. Scand J Clin Lab Invest 1977;37:333–338.

[8] Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976;17: 959–964.

[9] Schmidt LE, Ott P, Tygstrup N. Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience. Clin Gastroenterol Hepatol 2004;2:418–424.

[10] Merkel C, Marchesini G, Fabbri A, Bianco S, Bianchi G, Enzo E, et al. The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. Hepatology 1996;24:820–823.

[11] Jepsen P, Vilstrup H, Ott P, Keiding S, Andersen PK, Tygstrup N. The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study. BMC Gastroenterol 2009;30:50.

[12] Redaelli CA, Dufour JF, Wagner M, Schilling M, Hüsler J, Krähenbühl L, et al. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 2002;235:77–85.

[13] Sørensen M, Frisch K, Bender D, Keiding S. The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2011;38:1723–1731.

[14] Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60: 646–649.

[15] Nielsen NC. Correction for blank density in spectrophotometric dye determination in turbid plasma within the spectral range 600 to 920 nanometers (a method of universal applicability derived from Gaebler's law on the basis of simple theoretical considerations). Scand J Clin Lab Invest 1963;15: 610–612.

[16] Nielsen NC. Spectrophotometric determination of indocyanine green in plasma especially with a view to an improved correction for blank density. Scand J Clin Lab Invest 1963;15:613–621.

[17] Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 1987;7: 155–162.

[18] Frisch K, Bender D, Hansen SB, Keiding S, Sørensen M. Nucleophilic radiosynthesis of 2-[18F]fluoro-2-deoxy-D-galactose from Talose triflate and biodistribution in a porcine model. Nucl Med Biol 2011;38:477–483.

[19] Winkler K, Bass L, Henriksen J, Larsen OA, Ring P, Tygstrup N. Heterogeneity of splanchnic vascular transit times in man. Clin Physiol 1983;3:537–544.

[20] Winkler K, Bass L, Keiding S, Tygstrup N. The physiological basis for clearance measurements in hepatology. Scand J Gastroenterol 1979;14: 439–448.

[21] Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res Rev 1982;4:237–274.

[22] Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1–7.

[23] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–1457.

[24] Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004;40:475–483.

[25] Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005;15:497–501.

[26] Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523–525.

[27] Ballard FJ. Purification and properties of galactokinase from pig liver. Biochem J 1966;98:347–352.

[28] Keiding S, Johansen S, Winkler K, Tonnesen K, Tygstrup N. Michaelis–Menten kinetics of galactose elimination by the isolated perfused pig liver. Am J Physiol 1976;230:1302–1313.

[29] Keiding S, Sørensen M. Hepatic removal kinetics: importance for quantitative measurements of liver function. In: Rodés J, Benhamou JP, Blei A, Reichen J, Rizzetto M, editors. Textbook of hepatology. From basic science to clinical practice, vol. 1. London: Blackwell; 2007. p. 468–478.

[30] Sørensen M, Høyer M, Keiding S. Regional liver tissue damage induced by stereotactic radiotherapy of liver tumours quantified by [18F]fluoro-2-deoxy-galactose PET/CT. J Hepatol 2012;56:S395–S396.

[31] Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis – a histological classification of the severity of cirrhosis. J Hepatol 2006;44:111–117.

[32] Sethasine S, Jain D, Groszmann RJ, Garcia-Tsao G. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology 2012;55:1146–1153.